摘要
We have read the interesting paper by Costa and Saxenaentitled ‘‘Surgical chylothorax in neonates: management andoutcomes”, recently published in the World Journal of Pediatrics[ 1 ]. There are few points of the article that we wouldlike to discuss. We recently published a systematic reviewfocusing on the use of octreotide for congenital and acquiredchylothorax in newborns [ 2 ]. Our review concluded thatoctreotide was safe and eff ective in the treatment of chylothoraxin newborns, especially for the congenital forms, andthat octreotide therapy should be considered as an adjunctivetreatment in term and preterm neonates aff ected by congenitaland acquired chylothorax.
